Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347849 | 0.94 | CTSB (0.90) | CTSBBACE1 | |
| SCHEMBL14375061 | 0.94 | CTSB (0.90) | CTSBBACE1 | |
| SCHEMBL14375077 | 0.94 | CTSB (0.90) | CTSBBACE1 | |
| SCHEMBL4666527 | 0.93 | CTSB (1.00) | CTSBBACE1 | |
| SCHEMBL4666465 | 0.89 | CTSB (1.00) | CTSBBACE1 | |
| SCHEMBL14347784 | 0.89 | BACE1 (1.00) | CTSBBACE1 | |
| SCHEMBL14347860 | 0.89 | CTSB (1.00) | CTSBBACE1 | |
| SCHEMBL4668107 | 0.88 | CTSB (1.00) | CTSBBACE1 | |
| SCHEMBL14375163 | 0.86 | CTSB (1.00) | CTSBBACE1 | |
| SCHEMBL14347752 | 0.86 | CTSB (1.00) | CTSBBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | CTSB 2593/4885BACE1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.